Lilly pres Deirdre Connelly defects to GSK

Share this article:
Deirdre Connelly
Deirdre Connelly

In joint company statements today, GlaxoSmithKline and Lilly announced that Deirdre Connelly has resigned as president of US operations at Lilly, to become president, North American pharmaceuticals, at GlaxoSmithKline. Connelly will begin her new role at GSK on February 9, 2009.

In the statement, GSK CEO Andrew Witty said Connelly is “somebody who truly understands the needs of patients and our customers and can drive the efforts we are making to reshape this business and improve future growth.” Connelly had led Lilly's US operations since 2005.

Lilly, in turn, promoted Enrique Conterno, currently senior vice president of healthcare professional markets, to president, effective immediately. Conterno will report to Bryce Carmine, EVP of global marketing and sales.

Conterno “understands the complexities of the US marketplace, he has stressed the need to accelerate the transformation that is under way at this company, and he is focused on the needs of the patients we serve,” said John Lechleiter, Lilly's chairman, president and CEO, in a statement.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.